Monoclonal Antibodies for Chronic Pain Treatment: Present and Future
| Autor: | Nancy Paniagua, Carmen Rodríguez-Rivera, Rocío Girón, David Pascual, Carlos Goicoechea, Eva M. Sánchez-Robles |
|---|---|
| Přispěvatelé: | Sánchez-Robles, Eva M. [0000-0002-2740-2750], Girón, Rocío [0000-0001-8530-8378], Goicoechea, Carlos [0000-0002-6226-6934], Sánchez-Robles, Eva M., Girón, Rocío, Goicoechea, Carlos |
| Rok vydání: | 2021 |
| Předmět: |
QH301-705.5
medicine.drug_class Chronic pain Osteoarthritis Review Calcitonin gene-related peptide Monoclonal antibody Bioinformatics Catalysis Inorganic Chemistry Clinical Animals Humans Pain Management Medicine Biology (General) Physical and Theoretical Chemistry QD1-999 Molecular Biology Spectroscopy Analgesics business.industry Organic Chemistry Antibodies Monoclonal General Medicine medicine.disease Preclinical Computer Science Applications Chemistry Migraine Calcitonin Rheumatoid arthritis Tumor necrosis factor alpha Monoclonal antibodies business |
| Zdroj: | Digital.CSIC. Repositorio Institucional del CSIC instname International Journal of Molecular Sciences, Vol 22, Iss 10325, p 10325 (2021) International Journal of Molecular Sciences |
| Popis: | Chronic pain remains a major problem worldwide, despite the availability of various non-pharmacological and pharmacological treatment options. Therefore, new analgesics with novel mechanisms of action are needed. Monoclonal antibodies (mAbs) are directed against specific, targeted molecules involved in pain signaling and processing pathways that look to be very effective and promising as a novel therapy in pain management. Thus, there are mAbs against tumor necrosis factor (TNF), nerve growth factor (NGF), calcitonin gene-related peptide (CGRP), or interleukin-6 (IL- 6), among others, which are already recommended in the treatment of chronic pain conditions such as osteoarthritis, chronic lower back pain, migraine, or rheumatoid arthritis that are under preclinical research. This narrative review summarizes the preclinical and clinical evidence supporting the use of these agents in the treatment of chronic pain. This research received no external funding. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|